Thomas de Vamm

Founder & CEO

Yard Limited is founded by Thomas de Vamm, a science entrepreneur, who's vision is to make a significant contribution to humanity by improving global health in the 21 century. Thomas holds an international Bachelor's degree of Medicine and Global health, from the University of Groningen.

Daniel de Boeer

Director, non clinical development

Daniel de Boeer is a scientist with a background in protein folding and directed protein evolution. He holds a Master's Degree in Molecular Cell Biology and Biological Chemistry fro VU University Amsterdam. He was a Howard Hughes Medical Institute research scholar at the University of Michigan from 2006 to 2011, where he worked on developing in vivo models for studying protein folding. Daniel joined Yard Limited in February 2012 as the lead scientist in many projects.

Dinko Volerio

Supervisory board member

Dinko Volerio is a scientist and an experienced biotech entrepreneur with experience in both public and private companies as CEO and board member. Adding to his corporate experience, Mr Volerio is a professor in the field of gene therapy of the hematopoietic system at the University of Leiden. He is an author of more than 50 articles in peer-reviewed journals and an inventor of 5 patent-families.

Thomas Wosniewski

Advisory board member

Thomas Wosniewski obtained his Medical Degree at King's college School of Medicine in the UK. He did his Neurology and Neuropathology Residencies at NYU and Columbia-Presbyterian, respectively. He runs an active research laboratory focusing on neurodegenerative disorders, which has led to over 100 peer-reviewed publications.

Philip Scheltans

Advisory board member

Philip Scheltans has had an extensive career in drug development and pharma. He has more than one decade of experience in RNA drug development from discovery through drug registration, both in large pharma and biotech companies. Philip obtained his Phd in Molecular and Cellular Biology in the NYU.

Gerard Vlatenburg

Advisory board member

Gerard Vlatenburg has an extensive background in RNA modulation and orphan drug discovery and development and is in charge of our innovation unit. Gerard has more than 15 years of senior managerial experience, which he gained during his different operational and leadership roles in growing biothech companies. He is professor of Human Genetics in the Center for Molecular Medicine at the University Medical Center Utrecht.